Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Chronic effect of prindolol  (1)
  • Glukagon  (1)
  • Hyperlipidaemia  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 60 (1982), S. 651-657 
    ISSN: 1432-1440
    Keywords: Uremia ; cAMP ; lipolysis ; Glucagon ; Uremic metabolic disturbances ; Urämie ; cyclisches AMP ; Glukagon ; Lipolyse
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Vergleichend wurde der Effekt einer intravenös gegebenen Einzeldosis von Glukagon auf das Verhalten der cAMP-Konzentration im Plasma untersucht. Die Untersuchungen erfolgten an 7 gesunden Personen, 10 Patienten mit chronischer Niereninsuffizienz und 10 Patienten, die auf Grund des chronischen Nierenversagens einer Langzeithämodialysebehandlung bedurften. 10 min nach Glukagonanwendung zeigten die urämischen Patienten einen signifikanten (p 〈 0,0001) größeren Anstieg von cAMP im Vergleich zu der Kontrollgruppe. Die Glukosekonzentrationen zeigten nach Glukagon zwischen den beiden Gruppen keine Differenz. Die Lipolyse war in der urämischen Patientengruppe weniger stark ausgeprägt, als bei den Kontrollen (p 〈 0,003). Die Resultate ließen sich nicht auf Unterschiede in der Insulinantwort zurückführen. Die Befunde weisen auf ein unterschiedliches Verhalten der hepatischen Adenylatcyclase und der cAMP-Bildung zwischen gesunden und urämischen Personen hin. Diese Änderungen der cAMP-Aktivität können eine grundsätzliche Rolle bei der Pathophysiologie metabolischer Störungen bei Urämie spielen.
    Notes: Summary The effect of a single, intravenously administered dose of glucagon on plasma cyclic adenoside monophosphate (cAMP) was studied in seven normal subjects, ten patients with chronic renal failure (CRF), and ten patients with terminal renal insufficiency (TRI) receiving long-term haemodialysis treatment (HD). Ten minutes following glucagon administration, uremic patients displayed a significantly (P 〈 0.0001) greater increase in cAMP than control subjects. Glucose levels after glucagon administration did not differ significantly between the normal and uremic groups, and lipolysis was less pronounced in the uremic patients than in the controls (P 〈 0.003). These results could not be attributed to differences in serum insulin response. The findings demonstrate differences in the hepatic adenylate cyclase and cAMP response between normal and uremic subjects. These alterations in cAMP responsiveness may play a role in the pathophysiology of the metabolic disturbances associated with uremia.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1440
    Keywords: Hyperlipidaemia ; Cholesterol ; Triglycerides ; Uraemia ; Regular haemodialysis treatment ; Bezafibrate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Hyperlipidaemia may contribute to the high rate of cardiovascular complications in patients on chronic haemodialysis (CHD). However, possibilities of lipid lowering therapy in CHD are still limited. The applicability of bezafibrate (BF), a recently developed clofibrate analogue, was investigated in patients on CHD with triglyceride and/or total cholesterol levels above 300 mg/dl. The lipid lowering effect was studied in a placebo-controlled trial over 6 months in 19 patients. Long-term effect was followed in six patients over a mean period of 29 months. Elimination half-life and mean therapeutic serum concentration were calculated by 72-h BF serum profiles, obtained after the first drug administration of a single 200-mg dose and during steady state after 12 weeks of treatment. Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function. Dose reduction to 200 mg every 3rd day was necessary and resulted in a mean therapeutic serum concentration of 3.4 mg/l, which was similar to 3.0 mg/l of normal subjects, who received the dose optimal for lowering of lipids (200 mg 3 × /day). The protein-bound serum fraction of BF was decreased to 8% in CHD patients, compared with 95% found in normal subjects. BF therapy resulted in a marked reduction of serum triglycerides from 478 mg/dl by 31% and total cholesterol levels from 311 mg/dl by 19% as well as β-Lp-cholesterol from 178 mg/dl by 17%, whereas the initially low α-Lp-cholesterol increased significantly from 18,3 mg/dl by 58%. Under long-term therapy not only continuously low triglyceride and cholesterol levels could be maintained, moreover a further decline (−20% and −7%) could be achieved. Safety laboratory controls, comprising haemoglobin, bilirubin, liver enzymes, CK and albumin, showed no significant changes apart from a slight reversible increase in CK and a decrease in gamma-GT and alkaline phosphatase. Subjective side effects were not reported. Under this dosage schedule, BF therapy was thus effective and safe, improving potentially atherogenic disturbances of lipid metabolism.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 54 (1976), S. 1095-1105 
    ISSN: 1432-1440
    Keywords: Plasma-Noradrenalin ; Essentielle Hypertonie ; β-Sympathicolyse ; Essential hypertension ; Plasma noradrenaline ; Chronic effect of prindolol ; Mechanism of action of beta blockers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary 15 patients (4 females, 11 males, 21 to 55-year old) with mild to moderate essential hypertension (EH) were treated with placebo for two weeks and thereafter with increasing doses of prindolol (15 to 38 mg/day in the mean) and kept on a mean maintenance dosage of 32 mg/day for an average of 16 weeks in all. Blood pressure (BP), heart rate und plasma noradrenaline (PNA) concentrations were measured under standardized conditions (supine, standing, walking) at the end of two weeks on placebo and after the experimental treatment period. The results were compared to those of a group of 15 normotensive untreated control subjects (NS): after an average of 16 weeks on prindolol BP fell from 163/113 mm Hg to 129/91 mm Hg in the mean. PNA levels in EH before prindolol were significantly higher than in NS (supine: 272±22.0 ng/l (mean±SEM) vs. 135±15.1 ng/l, standing: 448±31.9 ng/l vs. 359±18.4 ng/l, walking: 388±22.5 ng/l vs. 234±22.1 ng/l). In EH chronic administration of prindolol led to a significant decrease in PNA concentrations under all the three test conditions to levels which did not differ significantly any more from those derived from NS. The adrenergic response to upright posture reflected in the percentage increase in PNA was significantly less in EH before prindolol when compared to the percentage increase in NS. On prindolol the adrenergic response was not abolished, yet it tended to approach the values found in NS. Before prindolol under resting conditions diastolic BP correlated closely with the corresponding PNA levels (p〈0.01,r=0.66,n=15). This correlation could not be reestablished after prindolol treatment. The decrease in PNA after long-term treatment with prindolol was not correlated to the fall in blood pressure. The decrease in PNA indicates a lower activity of the sympathetic nervous system which may contribute to the antihypertensive effect of prindolol.
    Notes: Zusammenfassung 15 Patienten (4 Frauen, 11 Männer; 21–55 Jahre alt) mit einer leichten bis mittelschweren essentiellen Hypertonie (EH) wurden nach einer 2wöchigen Placeboperiode mit steigenden Dosen von Prindolol behandelt (15–38 mg/die im Mittel) und auf einer Erhaltungsdosis von durchschnittlich 32 mg/die insgesamt 16 Wochen lang gehalten. Blutdruck (BD), Herzfrequenz und Plasmanoradrenalin (PNA)-Konzentration wurden unter standardisierten Bedingungen (liegen, stehen, gehen) am Ende der 2-wöchigen Placeboperiode und nach der experimentellen Behandlungsperiode gemessen. Die Ergebnisse wurden mit denen einer normotensiven, unbehandelten Kontrollgruppe (NS) verglichen. Nach durchschnittlich 16 Wochen Prindololbehandlung fiel der BD von 163/113 mm Hg auf 129/91 mm Hg im Mittel ab. Die PNA-Spiegel lagen bei EH vor Prindolol signifikant höher als bei NS (liegen: 272±22.0 ng/l (mean±SEM) vs. 135±15.1 ng/l, stehen: 448±31.9 ng/l vs. 359±18.4 ng/l, gehen: 388±22.5 ng/l vs. 234±22.1 ng/l). Bei EH führte die chronische Gabe von Prindolol zu einem signifikanten Abfall der PNA-Konzentrationen unter allen drei Testbedingungen auf Spiegel, die sich nicht mehr signifikant von denen der NS unterschieden. Die adrenerge Reaktion auf die aufrechte Körperhaltung, gemessen durch den prozentualen Anstieg der PNA, war signifikant geringer bei EH vor Prindolol, verglichen mit dem prozentualen Anstieg bei NS. Unter Prindolol war die adrenerge Reaktion nicht aufgehoben, sie zeigte sogar die Tendenz, sich den Verhältnissen anzugleichen wie sie bei NS gefunden wurden. Vor Prindolol korrelierte unter basalen Bedingungen der diastolische BD eng mit der entsprechenden PNA-Konzentration (p〈0.01,r=0.66,n=15). Diese Korrelation konnte nach der Prindolol-Behandlung nicht mehr aufgestellt werden. Die Abnahme von PNA nach Langzeitbehandlung mit Prindolol korrelierte nicht mit dem Abfall des BD. Die Abnahme des PNA-Spiegels spricht für eine verminderte Aktivität des sympathischen Nervensystems, die zur antihypertensiven Wirkung von Prindolol beitragen könnte.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...